} .hero h1{ color: $lt-green; font-weight: 400; font-size: 10px; @media (max-width: 991px) { font-size: 10px; font-weight: 500; } } EIP Pharma: treating neurodegenerative diseases

We believe the key to treating neurodegenerative disease is to intervene early.

Millions of people worldwide suffer from neurodegenerative diseases that impair memory, focus and thinking. Their ability to go about their daily lives is impacted by these progressive conditions. We believe that by applying our approach we can reverse the synaptic dysfunction that, ahead of death of nerve cells, is responsible for disease symptoms and progression.

Corporate Presentation

 EIP Pharma's Approach for Dementia with Lewy Bodies


Hope Through Science

Introducing Neflamapimod

We’re developing neflamapimod—an oral, selective small molecule inhibitor of the protein kinase p38 alpha. Extensive research has shown that p38 alpha is a key driver of synaptic dysfunction, the reversible aspect of the neurodegenerative process. The preclinical data with neflamapimod, along with evidence from recent phase 2 clinical studies in dementia with Lewy bodies (DLB) and in Alzheimer’s disease (AD), strongly suggest that inhibition of p38 alpha by neflamapimod reverses the synaptic dysfunction that underlies disease progression in the early stages of many neurological disorders.

Treatment & Results

EIP Pharma in the News